Why do phase III clinical trials in oncology fail so often?

Why do phase III clinical trials in oncology fail so often?

Achieving success in the development of a cancer drug continues to be challenging. Here, Amiri-Kordestani and Fojo discuss the high percentage of negative randomized clinical trials (RCTs) observed in the study by Gan et al. They also address the concepts of expected benefit and optimistic assumptio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JNCI : Journal of the National Cancer Institute 2012-04, Vol.104 (8), p.568-569
Hauptverfasser: Amiri-Kordestani, Laleh, Fojo, Tito
Format: Artikel
Sprache:eng
Schlagworte:
Antineoplastic Agents - therapeutic use
Cancer
Clinical trials
Clinical Trials, Phase III as Topic
Humans
Neoplasms - drug therapy
Oncology
Randomized Controlled Trials as Topic
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Achieving success in the development of a cancer drug continues to be challenging. Here, Amiri-Kordestani and Fojo discuss the high percentage of negative randomized clinical trials (RCTs) observed in the study by Gan et al. They also address the concepts of expected benefit and optimistic assumptions and conclude that true clinical benefits defined as prolongation of life should be the goal of RCTs.
ISSN:0027-8874
1460-2105
DOI:10.1093/jnci/djs180